# Ritlecitinib in CTCL

> **NCT05879458** · PHASE2 · TERMINATED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 7 (actual)

## Conditions studied

- CTCL
- Mycosis Fungoides
- Sezary Syndrome

## Interventions

- **DRUG:** Ritlecitinib

## Key facts

- **NCT ID:** NCT05879458
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-05-17
- **Primary completion:** 2025-06-25
- **Final completion:** 2025-06-25
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** No significant improvement in disease as graded by our assessments.
- **Last updated:** 2025-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05879458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05879458, "Ritlecitinib in CTCL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05879458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*